Evaluation of adverse drug reactions reported to a poison control center between 2000 and 2007

American Journal of Health-System Pharmacy

Volumn 66, Issue 5, 2009, Pages 481-487

  Vassilev, Zdravko P ^a,e   Chu, Alvin F ^f   Ruck, Brue ^b   Adams, Edgar H ^c,d   Marcus, Steven M ^b  

^a 206 Carnegie Center   (United States)

^b University of Medicine   (United States)

^c New Jersey Poison Information and Education System   (United States)

^d UK   (United States)

^e 206 Carnegie Center   (United States)

^f NONE

Author keywords

Adverse reactions; Drugs; Hospitals; Poison control centers; Poisoning; Reports

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIASTHMATIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTITUSSIVE AGENT; CARDIOVASCULAR AGENT; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; ELECTROLYTE; GASTROINTESTINAL AGENT; HERBACEOUS AGENT; HOMEOPATHIC AGENT; HORMONE; HORMONE ANTAGONIST; HYPNOTIC AGENT; MINERAL; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; SEDATIVE AGENT; TOPICAL AGENT; TOXOID; UNINDEXED DRUG; VACCINE; VITAMIN; DRUG;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; AGE; AGED; ARTICLE; CHILD; EVALUATION; FEMALE; GENDER; HEALTH CARE FACILITY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; POISON CENTER; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; UNSPECIFIED SIDE EFFECT; DRUG SURVEILLANCE PROGRAM; FACTUAL DATABASE; INFANT; MIDDLE AGED; STATISTICS; UNITED STATES;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTIDEPRESSIVE AGENTS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; INFANT; MALE; MIDDLE AGED; NEW JERSEY; PHARMACEUTICAL PREPARATIONS; POISON CONTROL CENTERS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 63049111471     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080267     Document Type: Article

References (34)

1. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36:1331-6.
2. Bates DW, Spell N, Cullen DJ et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997; 277:307-11.
3. Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J. 2001; 31:199-205.
4. Jha AK, Kuperman GJ, Rittenberg E et al. Identifying hospital admissions due to adverse drug events using a computer-based monitor. Pharmacoepidemiol Drug Saf. 2001; 10:113-9.
5. Woods DM, Thomas EJ, Holl JL et al. Ambulatory care adverse events and preventable adverse events leading to a hospital admission. Qual Saf Health Care. 2007; 16:127-31.
6. Johnston PE, France DJ, Byrne DW et al. Assessment of adverse drug events among patients in a tertiary care medical center. Am J Health-Syst Pharm. 2006; 63:2218-27.
7. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329:15-9.
8. Rivkin A. Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health-Syst Pharm. 2007; 64:1840-3.
9. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279:1200-5.
10. Budnitz DS, Pollock DA, Weidenbach KN et al. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006; 296:1858-66.
11. Palmer ME, Haller C, McKinney PE et al. Adverse events associated with dietary supplements: an observational study. Lancet. 2003; 361:101-6.
12. Dennehy CE, Tsourounis C, Horn AJ. Dietary supplement-related adverse events reported to the California poison control system. Am J Health-Syst Pharm. 2005; 62:1476-82.
13. Yang S, Dennehy CE, Tsourounis C. Characterizing adverse events reported to the California poison control system on herbal remedies and dietary supplements: a pilot study. J Herb Pharmacother. 2002; 2:1-11.
14. Peyriere H, Cassan S, Floutard E et al. Adverse drug events associated with hospital admission. Ann Pharmacother. 2003; 37:5-11.
15. Onder G, Pedone C, Landi F et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc. 2002; 50:1962-8.
16. Thomsen LA, Winterstein AG, Sondergaard B et al. Systemic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007; 41:1411-26.
17. Novak S, Nemeth WC, Lawson KA. Trends in medical use and abuse of sustained-release opioid analgesics: a revisit. Pain Med. 2004; 5:59-65.
18. Woolf CI, Hashmi M. Use and abuse of opioid analgesics: potential methods to prevent and deter nonmedical consumption of prescription opioids. Curr Opin Investig Drugs. 2004; 5:61-6.
19. Gaur AH, Hare ME, Shorr RI. Provider and practice characteristics associated with antibiotic use in children with presumed viral respiratory tract infections. Pediatrics. 2005; 115:635-41.
20. Gonzales R, Camargo CA, Mackenzie T et al. Antibiotic prescribing patterns for acute respiratory tract infections in acute care settings. Acad Emerg Med. 2006; 13:288-94.
21. Arroll B, Kenealy T. Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev. 2005; 3:CD000247.
22. McCaig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing rates for children and adolescents. JAMA. 2002; 287:3096-102.
23. Zaidenstein R, Eyal S, Efrati S et al. Adverse drug events in hospitalized patients treated with cardiovascular drugs and anticoagulants. Pharmacocpidemiol Drug Saf. 2002; 11:235-8.
24. Edoute Y, Nagachandran P, Svirski B et al. Cardiovascular adverse drug reactions associated with combined beta-adrenergic and calcium entry-blocking agents. J Cardiovasc Pharmacol. 2000; 35:556-9.
25. Frishman WH, Brosnan BD, Grossman M et al. Adverse dermatologic effects of cardiovascular drug therapy: part III. Cardiol Rev. 2002; 10:337-48.
26. Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dini-trate and hydralazine in blacks with heart failure. N Engl J Med. 2004; 351:2049-57. [Erratum, N Engl J Med. 2005; 352:1276.]
27. Vassilev ZP, Marcus SM. The impact of a poison control center on the length of hospital stay for patients with poisoning. J Toxicol Environ Health A. 2007; 70:107-10.
28. Gryzlak BM, Wallace RB, Zimmerman MB et al. National surveillance of herbal dietary supplement exposures: the poison control center experience. Pharmacoepi-demiol Drug Saf. 2007; 16:947-57.
29. Ruck B, Marcus S, Kashani I et al. Reply. Drug safety monitoring. JAMA. 2006; 296:1590. Letter.
30. Strom BL. How the US drug safety system should be changed. JAMA. 2006; 295:2072-5.
31. Litovitz T. The TESS database. Use in product safety assessment. Drug Saf. 1998; 18:9-19.
32. Cobaugh DJ, Krenzelok EP. Adverse drug reactions and therapeutic errors in older adults: a hazard factor analysis of poison center data. Am J Health-Syst Pharm. 2006; 63:2228-34.
33. Vassilev ZP, Marcus SM. Adverse interactions with antiretroviral agents: focus on recreational and addiction drugs. AIDS Read. 2004; 14:96. Letter.
34. Woolf A, Litovitz T. Reporting of adverse events. N Engl J Med. 2003; 348:1410-1. Letter.